

Table SIII. Incidence of adverse events under intravenous immunoglobulins (IVIg) therapy

Adverse event	Pemphigus (14) (PV, PnP, PF)		Pemphigoid (2) (BP, PnBP)		Overall (16)	
	Patients <i>n</i> (%)	Infusions <i>n</i> (%)	Patients <i>n</i> (%)	Infusions <i>n</i> (%)	Patients <i>n</i> (%)	Infusions <i>n</i> (%)
Headache	6 (42.9)	80 (27.1)	1 (50.0)	1 (2.1)	7 (43.8)	81 (23.6)
Fatigue	5 (35.7)	7 (2.4)	2 (100)	4 (8.3)	7 (43.8)	11 (3.2)
Back pain	4 (28.6)	30 (10.2)	1 (50.0)	1 (2.1)	5 (31.3)	31 (9.0)
Increased blood pressure	2 (14.3)	7 (2.4)	2 (100)	6 (12.5)	4 (25.0)	13 (3.8)
Decreased blood pressure	4 (28.6)	37 (12.5)	0 (0)	0 (0)	4 (25.0)	37 (10.8)
Nausea	3 (21.4)	4 (1.4)	0 (0)	0 (0)	3 (18.8)	4 (1.2)
Circulatory problems (vertigo/sweating)	3 (21.4)	8 (2.7)	0 (0)	0 (0)	3 (18.8)	8 (2.3)
Thoracic discomfort	0 (0)	0 (0)	1 (50.0)	2 (4.2)	1 (6.3)	2 (0.6)
Blurred vision	1 (7.1)	1 (0.3)	1 (50.0)	4 (8.3)	2 (12.5)	5 (1.5)
Skin symptoms	1 (7.1)	1 (0.3)	0 (0)	0 (0)	1 (6.3)	1 (0.3)
Allergic reaction	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Overall	12 (85.7)	175 (59.3)	2 (100)	18 (37.5)	14 (87.5)	193 (56.3)